137 related articles for article (PubMed ID: 35653869)
1. Synthesis of AC1903 analogs as potent transient receptor potential canonical channel 4/5 inhibitors and biological evaluation.
Chen L; Zhang Z; Tian H; Jiang S; Ji Y; Liu M; Shen J; Cao Z; Wang K
Bioorg Med Chem; 2022 Aug; 68():116853. PubMed ID: 35653869
[TBL] [Abstract][Full Text] [Related]
2. Nonselective TRPC channel inhibition and suppression of aminoglycoside-induced premature termination codon readthrough by the small molecule AC1903.
Baradaran-Heravi A; Bauer CC; Pickles IB; Hosseini-Farahabadi S; Balgi AD; Choi K; Linley DM; Beech DJ; Roberge M; Bon RS
J Biol Chem; 2022 Feb; 298(2):101546. PubMed ID: 34999117
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and characterization of novel N-heterocyclic-1-benzyl-1H-benzo[d]imidazole-2-amines as selective TRPC5 inhibitors leading to the identification of the selective compound, AC1903.
Sharma SH; Pablo JL; Montesinos MS; Greka A; Hopkins CR
Bioorg Med Chem Lett; 2019 Jan; 29(2):155-159. PubMed ID: 30538066
[TBL] [Abstract][Full Text] [Related]
4. A small-molecule inhibitor of TRPC5 ion channels suppresses progressive kidney disease in animal models.
Zhou Y; Castonguay P; Sidhom EH; Clark AR; Dvela-Levitt M; Kim S; Sieber J; Wieder N; Jung JY; Andreeva S; Reichardt J; Dubois F; Hoffmann SC; Basgen JM; Montesinos MS; Weins A; Johnson AC; Lander ES; Garrett MR; Hopkins CR; Greka A
Science; 2017 Dec; 358(6368):1332-1336. PubMed ID: 29217578
[TBL] [Abstract][Full Text] [Related]
5. Discovery of pyrroledione analogs as potent transient receptor potential canonical channel 5 inhibitors.
Zhang Z; Chen L; Tian H; Liu M; Jiang S; Shen J; Wang K; Cao Z
Bioorg Med Chem Lett; 2022 Apr; 61():128612. PubMed ID: 35143983
[TBL] [Abstract][Full Text] [Related]
6. Treatment with HC-070, a potent inhibitor of TRPC4 and TRPC5, leads to anxiolytic and antidepressant effects in mice.
Just S; Chenard BL; Ceci A; Strassmaier T; Chong JA; Blair NT; Gallaschun RJ; Del Camino D; Cantin S; D'Amours M; Eickmeier C; Fanger CM; Hecker C; Hessler DP; Hengerer B; Kroker KS; Malekiani S; Mihalek R; McLaughlin J; Rast G; Witek J; Sauer A; Pryce CR; Moran MM
PLoS One; 2018; 13(1):e0191225. PubMed ID: 29385160
[TBL] [Abstract][Full Text] [Related]
7. Charting a TRP to Novel Therapeutic Destinations for Kidney Diseases.
Pablo JL; Greka A
Trends Pharmacol Sci; 2019 Dec; 40(12):911-918. PubMed ID: 31704171
[TBL] [Abstract][Full Text] [Related]
8. Identification and optimization of 2-aminobenzimidazole derivatives as novel inhibitors of TRPC4 and TRPC5 channels.
Zhu Y; Lu Y; Qu C; Miller M; Tian J; Thakur DP; Zhu J; Deng Z; Hu X; Wu M; McManus OB; Li M; Hong X; Zhu MX; Luo HR
Br J Pharmacol; 2015 Jul; 172(14):3495-509. PubMed ID: 25816897
[TBL] [Abstract][Full Text] [Related]
9. Discovery of pyridazinone derivatives bearing tetrahydroimidazo[1,2-a]pyrazine scaffold as potent inhibitors of transient receptor potential canonical 5 to ameliorate hypertension-induced renal injury in rats.
Xu Y; Ren Y; Zhang J; Niu B; Liu M; Xu T; Zhang X; Shen J; Wang K; Cao Z
Eur J Med Chem; 2024 Jun; 275():116565. PubMed ID: 38878518
[TBL] [Abstract][Full Text] [Related]
10. Activation of TRPC cationic channels by mercurial compounds confers the cytotoxicity of mercury exposure.
Xu SZ; Zeng B; Daskoulidou N; Chen GL; Atkin SL; Lukhele B
Toxicol Sci; 2012 Jan; 125(1):56-68. PubMed ID: 21984481
[TBL] [Abstract][Full Text] [Related]
11. Discovery and pharmacological characterization of a novel potent inhibitor of diacylglycerol-sensitive TRPC cation channels.
Maier T; Follmann M; Hessler G; Kleemann HW; Hachtel S; Fuchs B; Weissmann N; Linz W; Schmidt T; Löhn M; Schroeter K; Wang L; Rütten H; Strübing C
Br J Pharmacol; 2015 Jul; 172(14):3650-60. PubMed ID: 25847402
[TBL] [Abstract][Full Text] [Related]
12. Stereo-selective inhibition of transient receptor potential TRPC5 cation channels by neuroactive steroids.
Majeed Y; Amer MS; Agarwal AK; McKeown L; Porter KE; O'Regan DJ; Naylor J; Fishwick CW; Muraki K; Beech DJ
Br J Pharmacol; 2011 Apr; 162(7):1509-20. PubMed ID: 21108630
[TBL] [Abstract][Full Text] [Related]
13. TRPC1 as a negative regulator for TRPC4 and TRPC5 channels.
Kim J; Ko J; Myeong J; Kwak M; Hong C; So I
Pflugers Arch; 2019 Aug; 471(8):1045-1053. PubMed ID: 31222490
[TBL] [Abstract][Full Text] [Related]
14. Further Exploration of the Benzimidazole Scaffold as TRPC5 Inhibitors: Identification of 1-Alkyl-2-(pyrrolidin-1-yl)-1H-benzo[d]imidazoles as Potent and Selective Inhibitors.
Sharma S; L Pablo J; Tolentino KT; Gallegos W; Hinman J; Beninato M; Asche M; Greka A; Hopkins CR
ChemMedChem; 2022 Jul; 17(14):e202200151. PubMed ID: 35557491
[TBL] [Abstract][Full Text] [Related]
15. A benzothiadiazine derivative and methylprednisolone are novel and selective activators of transient receptor potential canonical 5 (TRPC5) channels.
Beckmann H; Richter J; Hill K; Urban N; Lemoine H; Schaefer M
Cell Calcium; 2017 Sep; 66():10-18. PubMed ID: 28807145
[TBL] [Abstract][Full Text] [Related]
16. Effect of non-steroidal anti-inflammatory drugs and new fenamate analogues on TRPC4 and TRPC5 channels.
Jiang H; Zeng B; Chen GL; Bot D; Eastmond S; Elsenussi SE; Atkin SL; Boa AN; Xu SZ
Biochem Pharmacol; 2012 Apr; 83(7):923-31. PubMed ID: 22285229
[TBL] [Abstract][Full Text] [Related]
17. Selective Gαi subunits as novel direct activators of transient receptor potential canonical (TRPC)4 and TRPC5 channels.
Jeon JP; Hong C; Park EJ; Jeon JH; Cho NH; Kim IG; Choe H; Muallem S; Kim HJ; So I
J Biol Chem; 2012 May; 287(21):17029-17039. PubMed ID: 22457348
[TBL] [Abstract][Full Text] [Related]
18. Treasure troves of pharmacological tools to study transient receptor potential canonical 1/4/5 channels.
Rubaiy HN
Br J Pharmacol; 2019 Apr; 176(7):832-846. PubMed ID: 30656647
[TBL] [Abstract][Full Text] [Related]
19. The interaction domains of transient receptor potential canonical (TRPC)1/4 and TRPC1/5 heteromultimeric channels.
Myeong J; Ko J; Hong C; Yang D; Lee KP; Jeon JH; So I
Biochem Biophys Res Commun; 2016 Jun; 474(3):476-481. PubMed ID: 27131740
[TBL] [Abstract][Full Text] [Related]
20. Clemizole hydrochloride is a novel and potent inhibitor of transient receptor potential channel TRPC5.
Richter JM; Schaefer M; Hill K
Mol Pharmacol; 2014 Nov; 86(5):514-21. PubMed ID: 25140002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
